

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Brookes
Date of last notice	12 July 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	(a) Tarandi 1996 Pty Ltd <Dr DL Brookes Personal Superfund> <b>(Brookes Superfund)</b> (b) David and Elisabeth Brookes <Dahlbrook Family Trust> <b>(Dahlbrook Family Trust)</b>
Date of change	23 December 2024

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>No. of securities held prior to change</b>	<p><b>Direct</b></p> <p>(a) 1,240,000 Ordinary Shares  (b) 900,000 Options exercisable at \$0.225 each and expiring 14 November 2025 (450,000 vesting on 16 November 2022, 450,000 vesting on 16 November 2023);  (c) 175,000 Options exercisable at \$0.07 each and expiring on 11 December 2025  (d) 1,500,000 Options exercisable at \$0.10 each and expiring on 9 July 2028</p> <p><b>Indirect</b></p> <p><u>Brookes Superfund</u>  (a) 2,490,002 Ordinary Shares;  (b) 396,429 Options exercisable at \$0.07 each and expiring 11 December 2025;</p> <p><u>Dahlbrook Family Trust</u>  (a) 2,300,000 Ordinary Shares  (b) 1,000,000 Options exercisable at \$0.10 each and expiring 9 July 2028;  (c) 285,714 Options exercisable at \$0.07 each and expiring 11 December 2025.</p>
<b>Class</b>	Ordinary Shares & Options
<b>Number acquired</b>	<p>(a) 300,000 Ordinary Shares by Brookes Superfund  (b) 200,000 Ordinary Shares by Dahlbrook Family Trust</p>
<b>Number disposed</b>	Nil
<p><b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation</p>	\$25,000

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<p><b>Direct</b></p> <p>(a) 1,240,000 Ordinary Shares  (b) 900,000 Options exercisable at \$0.225 each and expiring 14 November 2025 (450,000 vesting on 16 November 2022, 450,000 vesting on 16 November 2023);  (c) 175,000 Options exercisable at \$0.07 each and expiring on 11 December 2025  (d) 1,500,000 Options exercisable at \$0.10 each and expiring on 9 July 2028.</p> <p><b>Indirect</b></p> <p><u>Brookes Superfund</u>  (a) 2,790,002 Ordinary Shares;  (b) 396,429 Options exercisable at \$0.07 each and expiring 11 December 2025;</p> <p><u>Dahlbrook Family Trust</u>  (a) 2,500,000 Ordinary Shares;  (b) 1,000,000 Options exercisable at \$0.10 each and expiring 9 July 2028;  (c) 285,714 Options exercisable at \$0.07 each and expiring 11 December 2025.</p>
<p><b>Nature of change</b>  Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Purchase of Ordinary Shares pursuant to Share Purchase Plan</p>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<p><b>No. and class of securities to which interest related prior to change</b>  Note: Details are only required for a contract in relation to which the interest has changed</p>	
<b>Interest acquired</b>	

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Anatara Lifesciences Limited</b>
<b>ABN</b>	<b>41 145 239 872</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	John Michailidis
<b>Date of last notice</b>	20 November 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	John Michailidis & Helen Michailidis <Michailidis Family Account>
<b>Date of change</b>	23 December 2024
<b>No. of securities held prior to change</b>	(a) 1,199,999 Ordinary Shares (b) 250,000 Unlisted Options exercisable at \$0.07 each and expiring 11 December 2025 (c) 1,000,000 Unlisted Options exercisable at \$0.10 each and expiring 9 July 2028 (d) 359,640 Performance Rights
<b>Class</b>	Ordinary Shares, Options and Performance Rights

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Number acquired</b>	100,000 Ordinary Shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$5,000
<b>No. of securities held after change</b>	(a) 1,299,999 Ordinary Shares (b) 250,000 Unlisted Options exercisable at \$0.07 each and expiring 11 December 2025 (c) 1,000,000 Unlisted Options exercisable at \$0.10 each and expiring 9 July 2028 (d) 359,640 Performance Rights
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Purchase of Ordinary Shares pursuant to Share Purchase Plan

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	

---

+ See chapter 19 for defined terms.

Interest after change	
-----------------------	--

**Part 3 – <sup>+</sup>Closed period**

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

<sup>+</sup> See chapter 19 for defined terms.